Novel agent DMAMCL suppresses osteosarcoma growth and decreases the stemness of osteosarcoma stem cell

References

• Isakoff MS, Bielack SS, Meltzer P, et al. Osteosarcoma: current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015;33:3029–3035.
   PubMed Web of Science ®Google Scholar
• Yan GN, Lv YF, Guo QN. Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets. Cancer Lett. 2016;370:268–274.
   PubMed Web of Science ®Google Scholar
• Gvozdenovic A, Arlt MJ, Campanile C, et al. CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome. J Bone Miner Res. 2013;28:838–847.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kaushik G, Subramaniam D, et al. Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy. J Hematol Oncol. 2017;10, 10. DOI:10.1186/s13045-016-0373-z.
   PubMed Web of Science ®Google Scholar
• Biermann JS, Chow W, Reed DR, et al. NCCN Guidelines Insights: bone Cancer, Version 2.2017. J Natl Compr Canc Netw. 2017;15:155–167.
   PubMed Web of Science ®Google Scholar
• Broadhead ML, Clark JC, Myers DE, et al. The molecular pathogenesis of osteosarcoma: a review. Sarcoma. 2011;2011:959248.
   PubMedGoogle Scholar
• Lu J, Song G, Tang Q, et al. MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1. Oncogene. 2017;36:231–241.
   PubMed Web of Science ®Google Scholar
• Abarrategi A, Tornin J, Martinez-Cruzado L, et al. Osteosarcoma: cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int. 2016;2016:3631764.
   PubMed Web of Science ®Google Scholar
• Gupte A, Baker EK, Wan SS, et al. Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clin Cancer Res. 2015;21:3216–3229.
   PubMed Web of Science ®Google Scholar
• Lin YH, Jewell BE, Gingold J, et al. Osteosarcoma: molecular Pathogenesis and iPSC Modeling. Trends Mol Med. 2017;23:737–755.
   PubMed Web of Science ®Google Scholar
• Yang J, Guo W, Wang L, et al. Cisplatin-resistant osteosarcoma cells possess cancer stem cell properties in a mouse model. Oncol Lett. 2016;12:2599–2605.
   PubMed Web of Science ®Google Scholar
• Viennois E, Xiao B, Ayyadurai S, et al. Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer. Lab Invest. 2014;94:950–965.
   PubMed Web of Science ®Google Scholar
• Ma WW, Shi QQ, Ding YH, et al. Synthesis of micheliolide derivatives and their activities against AML progenitor cells. Molecules. 2013;18:5980–5992.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lu Y, Ding Y, et al. Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. J Med Chem. 2012;55:8757–8769.
   PubMed Web of Science ®Google Scholar
• Jia Y, Zhang C, Zhou L, et al. Micheliolide overcomes KLF4-mediated cisplatin resistance in breast cancer cells by downregulating glutathione. Onco Targets Ther. 2015;8:2319–2327.
   PubMed Web of Science ®Google Scholar
• An Y, Guo W, Li L, et al. Micheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivo. PLoS One. 2015;10:e0116202.
   PubMed Web of Science ®Google Scholar
• Xu N, Hua Z, Ba G, et al. The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo. J Exp Clin Cancer Res. 2019;38:118.
   PubMed Web of Science ®Google Scholar
• Xiao W, Mohseny AB, Hogendoorn PC, et al. Mesenchymal stem cell transformation and sarcoma genesis. Clin Sarcoma Res. 2013;3:10.
   PubMedGoogle Scholar
• Mutsaers AJ, Walkley CR. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone. 2014;62:56–63.
   PubMed Web of Science ®Google Scholar
• Quist T, Jin H, Zhu JF, et al. The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse. Oncogene. 2015;34:4278–4284.
   PubMed Web of Science ®Google Scholar
• Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, et al. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/beta-catenin signaling. Cancer Lett. 2016;370:286–295.
   PubMed Web of Science ®Google Scholar
• Hua Z, Zhan Y, Zhang S, et al. P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB). Apoptosis. 2018;23:408–419.
   PubMed Web of Science ®Google Scholar
• Los M, Mozoluk M, Ferrari D, et al. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell. 2002;13:978–988.
   PubMed Web of Science ®Google Scholar
• Smulson ME, Simbulan-Rosenthal CM, Boulares AH, et al. Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1. Adv Enzyme Regul. 2000;40:183–215.
   PubMedGoogle Scholar
• Yokoyama T, Kohn EC, Brill E, et al. Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP. Int J Oncol. 2017. DOI:10.3892/ijo.2017.3914
   PubMed Web of Science ®Google Scholar
• Wion D, Berger F. Cancer stem cells. N Engl J Med. 2006;355:2703. author reply 2703.
   PubMed Web of Science ®Google Scholar
• Zhao J. Cancer stem cells and chemoresistance: the smartest survives the raid. Pharmacol Ther. 2016;160:145–158.
   PubMed Web of Science ®Google Scholar
• Ghantous A, Gali-Muhtasib H, Vuorela H, et al. What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today. 2010;15:668–678.
   PubMed Web of Science ®Google Scholar
• Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105:4163–4169.
   PubMed Web of Science ®Google Scholar
• Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007;110:4427–4435.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang Y. Cancer stem cells: models, mechanisms and implications for improved treatment. Cell Cycle. 2008;7:1360–1370.
   PubMed Web of Science ®Google Scholar
• Kawasaki BT, Hurt EM, Kalathur M, et al. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: an integrated molecular profiling approach. Prostate. 2009;69:827–837.
   PubMed Web of Science ®Google Scholar
• Neelakantan S, Nasim S, Guzman ML, et al. Aminoparthenolides as novel anti-leukemic agents: discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett. 2009;19:4346–4349.
   PubMed Web of Science ®Google Scholar
• Jia Y, Zhou L, Tian C, et al. Dynamin-related protein 1 is involved in micheliolide-induced breast cancer cell death. Onco Targets Ther. 2015;8:3371–3381.
   PubMed Web of Science ®Google Scholar
• Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 2006;43:1–67.
   PubMed Web of Science ®Google Scholar
• Siddiqui WA, Ahad A, Ahsan H. The mystery of BCL2 family: bcl-2 proteins and apoptosis: an update. Arch Toxicol. 2015;89:289–317.
   PubMed Web of Science ®Google Scholar
• Kim YR, Eom JI, Kim SJ, et al. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. J Pharmacol Exp Ther. 2010;335:389–400.
   PubMed Web of Science ®Google Scholar
• Visconti R, Della Monica R, Grieco D. Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword. J Exp Clin Cancer Res. 2016;35:153.
   PubMed Web of Science ®Google Scholar
• Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–348.
   PubMed Web of Science ®Google Scholar
• Cheah FK, Leong KH, Thomas NF, et al. Resveratrol analogue, (E)-N-(2-(4-methoxystyryl) phenyl) furan-2-carboxamide induces G2/M cell cycle arrest through the activation of p53-p21(CIP1/WAF1) in human colorectal HCT116 cells. Apoptosis. 2018;23:329–342.
   PubMed Web of Science ®Google Scholar
• Li HY, Zhang J, Sun LL, et al. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study. Cell Death Dis. 2015;6:e1604.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang T, Sun W, et al. Erianin induces G2/M-phase arrest, apoptosis, and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells in vitro and in vivo. Cell Death Dis. 2016;7:e2247.
   PubMed Web of Science ®Google Scholar
• Wang G, Zhang T, Sun W, et al. Arsenic sulfide induces apoptosis and autophagy through the activation of ROS/JNK and suppression of Akt/mTOR signaling pathways in osteosarcoma. Free Radic Biol Med. 2017;106:24–37.
   PubMed Web of Science ®Google Scholar
• Parida PK, Mahata B, Santra A, et al. Inhibition of cancer progression by a novel trans-stilbene derivative through disruption of microtubule dynamics, driving G2/M arrest, and p53-dependent apoptosis. Cell Death Dis. 2018;9:448.
   PubMed Web of Science ®Google Scholar
• Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in osteosarcoma. Cancer Lett. 2017;386:189–195.
   PubMed Web of Science ®Google Scholar